Roche Exit Strengthens Pfizer And Merck & Co In Covid Pill Market

US Stockpiling Could See Pfizer Earn $15bn-25bn

Molnupiravir
Merck & Co's molnupiravir (pictured) and Pfizer's PF-07321332 could be true 'game changers' in COVID-19 treatment once authorized for use. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip